Jump to main content

Knopp Biosciences

Knopp Biosciences

News Archive

Knopp Neurosciences Completes First Series B Financing of $10 Million

January 22, 2008

PITTSBURGH, Pa., January 22, 2008--Knopp Neurosciences Inc. ("Knopp") said it completed a Series B funding round of $10 million, increasing its total capitalization to $20 million.

The latest financing involved the exercise of milestone-based callable warrants held by existing investors in Knopp. The company anticipates making a further Series B call of $10 million following the initiation of Phase 2 studies of KNS-760704 in amyotrophic lateral sclerosis (ALS).

"Our funding arrangements will meet our capital requirements so long as we continue to achieve the milestones we established with our investors in advance," said Michael Bozik, M.D., president and CEO of Knopp. "Hitting value creation milestones provides our investors with an objective measure for judging our performance and confidence that we'll continue to efficiently advance our programs in ALS and neurodegeneration."

Saturn Capital Inc. of Boston acted as exclusive placement agent for Knopp's Series A and Series B financings. Participants in the latest financing included investors in Knopp's $10 million Series A round of late 2006, including Saturn Partners II of Boston, Kramer Capital Partners of Stamford, CT, and LaunchCyte LLC of Pittsburgh.

Knopp expects to initiate Phase 2 studies of KNS-760704 in early 2008.

About KNS 760704

KNS 760704 is a chirally pure, oral formulation of the synthetic amino-benzothiazole (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). Like its S(-) optical enantiomer, pramipexole dihydrochloride (Mirapex®), KNS-760704 has been shown to be effective in a range of neuroprotective assays. Unlike Mirapex®, a selective, high affinity dopamine agonist approved for the treatment of Parkinson's Disease, KNS 760704 exhibits very limited dopamine receptor affinity, making it possible to clinically evaluate its potential neuroprotective activity over a broad dose range. The compound's use in ALS has received orphan drug designation from the U.S. Food and Drug Administration. Phase 1 studies in healthy volunteers have been completed.

About ALS

Amyotrophic lateral sclerosis, often called Lou Gehrig's disease, is a rapid, universally fatal neurodegenerative disorder characterized by progressive muscle weakness and wasting. ALS affects adults in the prime of life and creates a substantial burden for caregivers. U.S. prevalence is approximately 30,000 and the incidence is nearly 2 per 100,000. Only a single drug has been approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc.

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS 760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led by Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

Mirapex® is a registered trademark of Boehringer Ingelheim Pharma KG Corporation.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS 760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact:
Thomas Petzinger Jr.